Investigating the Pharmacokinetic and Pharmacodynamic Profiles Following Continuous Subcutaneous Infusion of Insulin Aspart or Injection of Insulin Glargine in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Insulin aspart; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 16 Jun 2009 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
- 16 Jun 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
- 11 Jun 2009 Actual number of patients changed from 21 to 22 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History